"As we move toward the industry evolution, we're learning that there are some challenges associated with viral gene therapy and we've moved to, I think, based on the pandemic, a huge welcoming of mRNA and it's obvious from the vaccine perspective," Nguyen told ScienceBoard.net. "Certainly, from that continuum, you can imagine a benefit associated, not only with mRNA, but I would call nucleic acid delivery and specifically for our company we focus on DNA delivery."

Nguyen, whose biotech company is developing a novel DNA-delivered gene therapy platform to treat pathologic inflammation through immune modulation, will be a panelist in two separate panels on June 14 and June 15 at the 2022 Biotechnology Innovation Organization (BIO) International Convention in San Diego.

The June 15 BIO panel, "A New Era in Gene Therapy," will address accessibility concerns ranging from drug development efficacy to safe therapeutic vectors and how to improve manufacturing to broaden the application of gene therapy to challenging diseases.

Watch the video below to learn more.

Biotech innovator recounts decades-long journey to create drug discovery technology
Dr. Stan Crooke, PhD, founder, chairman, and chief executive officer of RNA therapy company Ionis Pharmaceuticals, pioneered development of the antisense...

Biotech industry to gather at BIO International Convention in San Diego
More than 11,000 attendees from around the globe will be in San Diego, June 13-16, for the 2022 Biotechnology Innovation Organization (BIO) International...

Juniper Biologics acquires cell-mediated gene therapy TG-C LD
Juniper Biologics has acquired the licensing rights to develop and commercialize TissueGene-C low dose (TG-C LD), a cell therapy-based treatment for knee...